Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Sponsor: Active Biotech AB
Terminated
Slow accrual at the time when sufficient participants were already enrolled to answer the scientific question posed by the study.
This PHASE1 trial investigates Multiple Myeloma and is currently terminated or withdrawn. Active Biotech AB leads this study, which shows 17 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
17 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jun 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Mar 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
▶ Show 12 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — May 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Active Biotech AB
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .